PI3K/PTEN signaling in angiogenesis and tumorigenesis.

[1]  T. Dai,et al.  SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. , 2008, Atherosclerosis.

[2]  K. Shokat,et al.  Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. , 2008, Cancer research.

[3]  Seung Yong Park,et al.  Mast cells can mediate vascular permeability through regulation of the PI3K-HIF-1alpha-VEGF axis. , 2008, American journal of respiratory and critical care medicine.

[4]  B. Jiang,et al.  Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. , 2008, Cancer research.

[5]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[6]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[7]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Bin Zhao,et al.  PTEN acetylation modulates its interaction with PDZ domain. , 2008, Cancer research.

[9]  M. Jeschke.  Faculty Opinions recommendation of Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. , 2008 .

[10]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[11]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[12]  Z. Gong,et al.  K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis , 2008, PloS one.

[13]  X. Liu,et al.  Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. , 2008, Neoplasia.

[14]  B. Keiper,et al.  Depletion of the cap-associated isoform of translation factor eIF4G induces germline apoptosis in C. elegans , 2008, Cell Death and Differentiation.

[15]  C. Benes,et al.  Class 1A PI3K regulates vessel integrity during development and tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[16]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[17]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[18]  D. Cheresh,et al.  H-Ras Regulates Angiogenesis and Vascular Permeability by Activation of Distinct Downstream Effectors , 2008, Circulation research.

[19]  Holger Gerhardt,et al.  Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.

[20]  P. Platzer,et al.  Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. , 2008, American journal of human genetics.

[21]  Seth B. Furgeson,et al.  Targeted Deletion of PTEN in Smooth Muscle Cells Results in Vascular Remodeling and Recruitment of Progenitor Cells Through Induction of Stromal Cell–Derived Factor-1&agr; , 2008, Circulation research.

[22]  F. Natt,et al.  Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. , 2008, Cell metabolism.

[23]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[24]  T. Salo,et al.  Tumor microenvironment and angiogenesis. , 2008, Frontiers in bioscience : a journal and virtual library.

[25]  J. Dipersio,et al.  A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies , 2008, Clinical Cancer Research.

[26]  M. Shibuya.  Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. , 2008, BMB reports.

[27]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Haase,et al.  The VHL tumor suppressor and HIF: insights from genetic studies in mice , 2008, Cell Death and Differentiation.

[30]  M. Shibuya,et al.  VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[31]  J. Griffin,et al.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. , 2008, Blood.

[32]  H. Aburatani,et al.  ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. , 2008, Cell metabolism.

[33]  D. Radisky,et al.  Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development , 2008, Clinical & Experimental Metastasis.

[34]  T. Mak,et al.  PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a) , 2008, Proceedings of the National Academy of Sciences.

[35]  D. Agrawal,et al.  Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease , 2008, Journal of cellular and molecular medicine.

[36]  Michael Karin,et al.  NF-kappaB and cancer-identifying targets and mechanisms. , 2008, Current opinion in genetics & development.

[37]  C. Eng,et al.  The nuclear affairs of PTEN , 2008, Journal of Cell Science.

[38]  J. Cheng.  Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ] , 2008 .

[39]  W. Kong,et al.  Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. , 2008, Current cancer drug targets.

[40]  A. Tolcher,et al.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[42]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[43]  O. Haas,et al.  Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia , 2007, European journal of clinical investigation.

[44]  B. Esmaeli,et al.  Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. , 2007, Ophthalmology.

[45]  B. Jiang,et al.  PI3K/PTEN signaling in tumorigenesis and angiogenesis. , 2008, Biochimica et biophysica acta.

[46]  C. Sotiriou,et al.  The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. , 2008, European journal of cancer.

[47]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[48]  G. Mills,et al.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. , 2008, Cancer research.

[49]  G. Pond,et al.  A Phase 2 study of perifosine in advanced or metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[50]  M. Andersson,et al.  Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer , 2008, International Journal of Clinical Oncology.

[51]  Susan M. Chang,et al.  Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[52]  J. Pinski,et al.  The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. , 2007, Clinical genitourinary cancer.

[53]  Lily Yang,et al.  PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. , 2007, Cellular signalling.

[54]  T. Kietzmann,et al.  Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. , 2007, Molecular biology of the cell.

[55]  David Stokoe,et al.  New insights into PTEN , 2007, Journal of Cell Science.

[56]  M. Hidalgo,et al.  A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  P. Houghton,et al.  Phase I study of everolimus in pediatric patients with refractory solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Paradiso Angelo,et al.  Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here? , 2007, Clinical Cancer Research.

[59]  Pingfu Fu,et al.  Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion , 2007, International journal of cancer.

[60]  Dexin Kong,et al.  ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms , 2007, Cancer science.

[61]  T. Mak,et al.  Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. , 2007, The Journal of clinical investigation.

[62]  V. Sukhatme,et al.  The FASEB Journal • Research Communication Activation of the orphan endothelial receptor Tie1 , 2022 .

[63]  R. Motzer,et al.  Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  K. Götze,et al.  Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia , 2007, Haematologica.

[65]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[66]  M. Kris,et al.  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer , 2007, Cancer.

[67]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[68]  Sumithra J Mandrekar,et al.  Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  Hong Wu,et al.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.

[70]  A. Suzuki,et al.  Non‐alcoholic steatohepatitis and hepatocellular carcinoma: Lessons from hepatocyte‐specific phosphatase and tensin homolog (PTEN)‐deficient mice , 2007, Journal of Gastroenterology and Hepatology.

[71]  P. Pandolfi,et al.  The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.

[72]  B. Gaston,et al.  Akt-mediated activation of HIF-1 in pulmonary vascular endothelial cells by S-nitrosoglutathione. , 2007, American journal of respiratory cell and molecular biology.

[73]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[74]  Jie Zhou,et al.  Akt1 governs breast cancer progression in vivo , 2007, Proceedings of the National Academy of Sciences.

[75]  T. Sasaki,et al.  Role of PTEN/PI3K pathway in endothelial cells. , 2007, Biochemical Society transactions.

[76]  M. Falasca,et al.  Role of class II phosphoinositide 3-kinase in cell signalling. , 2007, Biochemical Society transactions.

[77]  O. Livnah,et al.  A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. , 2007, Biochemistry.

[78]  R. Stenne,et al.  The Scaffolding Adapter Gab1 Mediates Vascular Endothelial Growth Factor Signaling and Is Required for Endothelial Cell Migration and Capillary Formation* , 2007, Journal of Biological Chemistry.

[79]  A. Benson,et al.  A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma , 2007, American journal of clinical oncology.

[80]  K. Sabapathy,et al.  c-Jun promotes cellular survival by suppression of PTEN , 2007, Cell Death and Differentiation.

[81]  A. C. Williams,et al.  Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia , 2007, Nature Cell Biology.

[82]  W. Yung,et al.  Mitogen-activated Protein Kinase Kinase-4 Promotes Cell Survival by Decreasing PTEN Expression through an NFκB-dependent Pathway* , 2006, Journal of Biological Chemistry.

[83]  A. C. Williams,et al.  Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. , 2007, Nature cell biology.

[84]  T. Nakao,et al.  Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling. , 2007, Journal of pharmacological sciences.

[85]  A. Paradiso,et al.  Phosphatidylinositol 3-kinase in breast cancer: where from here? , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  D. Ettinger,et al.  Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma , 2006, Cancer.

[87]  H. Yoshida,et al.  Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. , 2006, International journal of oncology.

[88]  P. Vogt,et al.  A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability , 2006, Journal of cellular physiology.

[89]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[90]  Anthony J. Muslin,et al.  Akt2 Regulates Cardiac Metabolism and Cardiomyocyte Survival* , 2006, Journal of Biological Chemistry.

[91]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[92]  G. Pond,et al.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas , 2006, British Journal of Cancer.

[93]  T. Haas,et al.  JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells. , 2006, American journal of physiology. Cell physiology.

[94]  Xianglin Shi,et al.  Regulation of angiogenesis and tumor growth by p110 Alpha and AKT1 via VEGF expression , 2006, Journal of cellular physiology.

[95]  N. Hay,et al.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.

[96]  J. Buckner,et al.  A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[97]  N. Leslie.  The redox regulation of PI 3-kinase-dependent signaling. , 2006, Antioxidants & redox signaling.

[98]  M. Konopleva,et al.  Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[99]  T. Mak,et al.  Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. , 2006, Cancer research.

[100]  J. Salles,et al.  The Adaptor Protein Gab1 Couples the Stimulation of Vascular Endothelial Growth Factor Receptor-2 to the Activation of Phosphoinositide 3-Kinase* , 2006, Journal of Biological Chemistry.

[101]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[102]  H. Bartelink,et al.  Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[103]  L. Ellis,et al.  Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. , 2006, Cancer cell.

[104]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[105]  V. Rus,et al.  C5b-9-induced Endothelial Cell Proliferation and Migration Are Dependent on Akt Inactivation of Forkhead Transcription Factor FOXO1* , 2006, Journal of Biological Chemistry.

[106]  J. Dancey,et al.  A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer , 2006, Cancer biology & therapy.

[107]  F. Das,et al.  Mesangial Cell Hypertrophy by High Glucose Is Mediated by Downregulation of the Tumor Suppressor PTEN , 2006, Diabetes.

[108]  X. Yao,et al.  Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel‐Lindau suppression and HIF1α activation , 2006, International journal of cancer.

[109]  Arne Gericke,et al.  Regulation of the PTEN phosphatase. , 2006, Gene.

[110]  D. Chung,et al.  Hypoxic Regulation of Vascular Endothelial Growth Factor through the Induction of Phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc* , 2006, Journal of Biological Chemistry.

[111]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[112]  L. Cantley,et al.  Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. , 2006, Cell metabolism.

[113]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[114]  S. Hirono,et al.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.

[115]  M. Neeman,et al.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. , 2006, Cancer cell.

[116]  G. Mills,et al.  The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. , 2006, Oral oncology.

[117]  J. Coselli,et al.  Up-regulation of PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome Ten) Mediates p38 MAPK Stress Signal-induced Inhibition of Insulin Signaling , 2006, Journal of Biological Chemistry.

[118]  E. Eisenhauer,et al.  A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial , 2006, Investigational New Drugs.

[119]  S. Hewitt,et al.  Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt , 2006, Molecular Cancer Therapeutics.

[120]  R. Memmott,et al.  Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway , 2006, Clinical Cancer Research.

[121]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[122]  R. McLendon,et al.  Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.

[123]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[124]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[125]  S. Moncada,et al.  Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. , 2006, Cancer research.

[126]  K. Ogasawara,et al.  Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300) , 2006, Brain Tumor Pathology.

[127]  K. Ballmer-Hofer,et al.  The role of VEGF receptors in angiogenesis; complex partnerships , 2006, Cellular and Molecular Life Sciences.

[128]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[129]  J. Rubin,et al.  Rapid, Wnt-Induced Changes in GSK3β Associations that Regulate β-Catenin Stabilization Are Mediated by Gα Proteins , 2005, Current Biology.

[130]  R. Jaffe,et al.  Phosphatidylinostol 3-Kinase Mediates Angiogenesis and Vascular Permeability Associated with Ovarian Carcinoma , 2005, Clinical Cancer Research.

[131]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[132]  R. DePinho,et al.  Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy , 2005, Molecular and Cellular Biology.

[133]  J. Fisher,et al.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. , 2005, Neoplasia.

[134]  N. Hay,et al.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.

[135]  S. Steinberg,et al.  A phase II study of perifosine in androgen independent prostate cancer , 2005, Cancer biology & therapy.

[136]  Wei Fang Chen,et al.  Diosgenin Induces Hypoxia-Inducible Factor-1 Activation and Angiogenesis through Estrogen Receptor-Related Phosphatidylinositol 3-kinase/Akt and p38 Mitogen-Activated Protein Kinase Pathways in Osteoblasts , 2005, Molecular Pharmacology.

[137]  Adolfo Saiardi,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. , 2005, Cancer research.

[138]  D. Trisciuoglio,et al.  Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. , 2005, Molecular biology of the cell.

[139]  R. DePinho,et al.  Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. , 2005, Cancer cell.

[140]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  M. Birnbaum,et al.  Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis , 2005 .

[143]  K. Alitalo,et al.  Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. , 2005, Cancer research.

[144]  T. Matsuyama,et al.  Angiopoietin 1 is mitogenic for cultured endothelial cells. , 2005, Cancer research.

[145]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[146]  T. H. van der Kwast,et al.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.

[147]  Yunbi Lu,et al.  Production of matrix metalloproteinase‐9 by activated human monocytes involves a phosphatidylinositol‐3 kinase/Akt/IKKα/NF‐κB pathway , 2005, Journal of leukocyte biology.

[148]  Thomas Kirchner,et al.  Invasion and Metastasis in Colorectal Cancer: Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition, Stem Cells and β-Catenin , 2005, Cells Tissues Organs.

[149]  R. Nussbaum,et al.  Deficiency in the p110alpha subunit of PI3K results in diminished Tie2 expression and Tie2(-/-)-like vascular defects in mice. , 2005, Blood.

[150]  Hee June Choi,et al.  Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes , 2005, Nature.

[151]  P. Frost,et al.  PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors , 2005, Cancer biology & therapy.

[152]  Sheila M. Thomas,et al.  Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement , 2005, Molecular and Cellular Biology.

[153]  Bing-Hua Jiang,et al.  Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[154]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[155]  G. Casey,et al.  The AKT/IκB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κB and β-catenin , 2005, Oncogene.

[156]  M. Birnbaum,et al.  Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. , 2005, The Journal of clinical investigation.

[157]  J. Rubin,et al.  Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. , 2005, Current biology : CB.

[158]  T. Tsuruo,et al.  3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. , 2005, The Journal of biological chemistry.

[159]  G. Casey,et al.  The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. , 2005, Oncogene.

[160]  Yunbi Lu,et al.  Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. , 2005, Journal of leukocyte biology.

[161]  A. Richmond,et al.  Role of nuclear factor-kappa B in melanoma. , 2005, Cancer metastasis reviews.

[162]  G. Wilding,et al.  A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer , 2004, Clinical Cancer Research.

[163]  D. Gutmann,et al.  Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo , 2004, Cancer Research.

[164]  Susan M. Chang,et al.  Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs , 2004, Investigational New Drugs.

[165]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[166]  F. Agani,et al.  Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1α, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling* , 2004, Journal of Biological Chemistry.

[167]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[168]  T. Mak,et al.  Tumorigenesis facilitated by Pten deficiency in the skin: Evidence of p53‐Pten complex formation on the initiation phase , 2004, Cancer science.

[169]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[170]  D. Hallahan,et al.  A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3′-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction , 2004, Cancer Research.

[171]  E. Paraskeva,et al.  Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by a reactive oxygen species- and PI3K-dependent mechanism. , 2004, American journal of respiratory cell and molecular biology.

[172]  Ching‐Jen Wang,et al.  Nitric oxide mediates ultrasound-induced hypoxia-inducible factor-1alpha activation and vascular endothelial growth factor-A expression in human osteoblasts. , 2004, Bone.

[173]  E. Raymond,et al.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[175]  G. Sonenshein,et al.  Reciprocal Control of Forkhead box O 3a and c-Myc via the Phosphatidylinositol 3-Kinase Pathway Coordinately Regulates p27Kip1 Levels1 , 2004, The Journal of Immunology.

[176]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[177]  Sung Hyun Kim,et al.  COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[178]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[179]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  T. Mak,et al.  Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[181]  D. Voskas,et al.  Inhibition of Tie-2 Signaling Induces Endothelial Cell Apoptosis, Decreases Akt Signaling and Induces Endothelial Cell Expression of the Endogenous Anti-Angiogenic Molecule, Thrombospondin-1 , 2004, Cancer biology & therapy.

[182]  E. Hafen,et al.  Targeted Expression of the Class II Phosphoinositide 3-Kinase in Drosophila melanogaster Reveals Lipid Kinase-Dependent Effects on Patterning and Interactions with Receptor Signaling Pathways , 2004, Molecular and Cellular Biology.

[183]  K. Reddy,et al.  Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.

[184]  G. Powis,et al.  In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. , 2004, Oncology Research.

[185]  J. Doroshow,et al.  CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. , 2004, Cancer.

[186]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[187]  Ying Qi,et al.  Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization* , 2003, Journal of Biological Chemistry.

[188]  D. Attaix,et al.  Class III phosphoinositide 3-kinase--Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes. , 2003, The Biochemical journal.

[189]  Tony Hunter,et al.  Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. , 2003, Cancer cell.

[190]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[191]  Hongbing Zhang,et al.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. , 2003, The Journal of clinical investigation.

[192]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[193]  R. Montesano,et al.  Loss of active MEK1-ERK1/2 restores epithelial phenotype and morphogenesis in transdifferentiated MDCK cells. , 2003, American journal of physiology. Cell physiology.

[194]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[195]  Brian A. Hemmings,et al.  Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth* , 2003, Journal of Biological Chemistry.

[196]  D. Mottet,et al.  Regulation of Hypoxia-inducible Factor-1α Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Pathway in HepG2 Cells* , 2003, Journal of Biological Chemistry.

[197]  W. Friedrichs,et al.  Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[198]  J. Stock,et al.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.

[199]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[200]  H. Murata,et al.  Phosphoinositide-dependent Kinase-2 Is a Distinct Protein Kinase Enriched in a Novel Cytoskeletal Fraction Associated with Adipocyte Plasma Membranes* , 2003, Journal of Biological Chemistry.

[201]  D. Stewart,et al.  Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. , 2003, The American journal of pathology.

[202]  C. Punt,et al.  Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[203]  Alfonso Bellacosa,et al.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.

[204]  T. Mak,et al.  Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production , 2003, Development.

[205]  B. Hemmings,et al.  Protein kinase B alpha/Akt1 regulates placental development and fetal growth. , 2003, The Journal of biological chemistry.

[206]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[207]  E. Lam,et al.  Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D , 2002, Molecular and Cellular Biology.

[208]  B. Hemmings,et al.  PKB Binding Proteins Getting in on the Akt , 2002, Cell.

[209]  J. Tavaré,et al.  The Identification of ATP-citrate Lyase as a Protein Kinase B (Akt) Substrate in Primary Adipocytes* , 2002, The Journal of Biological Chemistry.

[210]  L. Hennighausen,et al.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. , 2002, Development.

[211]  J. Schellens,et al.  Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. , 2002, European journal of cancer.

[212]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[213]  W. Fiedler,et al.  Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO) , 2002, Leukemia.

[214]  S. Snyder,et al.  Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[215]  G. Panayotou,et al.  Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. , 2002, Cancer cell.

[216]  E. J. Song,et al.  Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. , 2002, Cell.

[217]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[218]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[219]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[220]  M. Wheeler,et al.  Recruitment of the Class II Phosphoinositide 3-Kinase C2β to the Epidermal Growth Factor Receptor: Role of Grb2 , 2001, Molecular and Cellular Biology.

[221]  I. Roninson,et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.

[222]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[223]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[224]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[225]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[226]  N. Rahimi,et al.  Identification of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell Proliferation* , 2001, The Journal of Biological Chemistry.

[227]  I. Pass,et al.  Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN , 2001, Current Biology.

[228]  K. Alitalo,et al.  Tie receptors: new modulators of angiogenic and lymphangiogenic responses , 2001, Nature Reviews Molecular Cell Biology.

[229]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[230]  Y. Harima,et al.  Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. , 2001, International journal of oncology.

[231]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[232]  K. Kaestner,et al.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). , 2001, Science.

[233]  R. B. Campbell,et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy , 2001, Nature Medicine.

[234]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[235]  C. Peyssonnaux,et al.  Induction of Postmitotic Neuroretina Cell Proliferation by Distinct Ras Downstream Signaling Pathways , 2000, Molecular and Cellular Biology.

[236]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[237]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[238]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[239]  T. Mak,et al.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. , 2000, Cancer research.

[240]  M. Zvelebil,et al.  Class II Phosphoinositide 3-Kinases Are Downstream Targets of Activated Polypeptide Growth Factor Receptors , 2000, Molecular and Cellular Biology.

[241]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[242]  P. Vogt,et al.  Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[243]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[244]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[245]  K. Alitalo,et al.  Identification of Tek/Tie2 Binding Partners , 1999, The Journal of Biological Chemistry.

[246]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[247]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[248]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[249]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[250]  P. Donahoe,et al.  Requirement for phosphatidylinositol-3'-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. , 1999, Endocrinology.

[251]  F. Alt,et al.  Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. , 1999, Science.

[252]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[253]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[254]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[255]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[256]  J. Downward.  Mechanisms and consequences of activation of protein kinase B/Akt. , 1998, Current opinion in cell biology.

[257]  S. Schwartz,et al.  Deletion 10q23.2‐q23.33 in a patient with gastrointestinal juvenile polyposis and other features of a Cowden‐like syndrome , 1998, Genes, chromosomes & cancer.

[258]  J. Dixon,et al.  A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast* , 1997, The Journal of Biological Chemistry.

[259]  C. Larsson,et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.

[260]  J. Ott,et al.  The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. , 1997, American journal of human genetics.

[261]  A. Giaccia,et al.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.

[262]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[263]  F. McCormick,et al.  Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. , 1997, Science.

[264]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[265]  G. Panayotou,et al.  Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.

[266]  M. Waterfield,et al.  Using structure to define the function of phosphoinositide 3‐kinase family members , 1997, FEBS letters.

[267]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[268]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[269]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[270]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[271]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[272]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[273]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[274]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[275]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[276]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[277]  P. Warne,et al.  Phosphatidylinositol 3' kinase: one of the effectors of Ras. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[278]  P. Polakis,et al.  Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. , 1996, Science.

[279]  M. Waxham,et al.  Interaction of the Flt-1 Tyrosine Kinase Receptor with the p85 Subunit of Phosphatidylinositol 3-Kinase , 1995, The Journal of Biological Chemistry.

[280]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[281]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[282]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[283]  J. Folkman.  Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[284]  A. Saltiel,et al.  Direct analysis of the binding of Src-homology 2 domains of phospholipase C to the activated epidermal growth factor receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[285]  A. Reith,et al.  SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors , 1992, Molecular and cellular biology.

[286]  A. Ullrich,et al.  Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors , 1992, Molecular and cellular biology.

[287]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[288]  G. Panayotou,et al.  Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase , 1991, Cell.

[289]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[290]  L. Cantley,et al.  Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation , 1985, Nature.

[291]  L. Cantley,et al.  Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. , 1984, Proceedings of the National Academy of Sciences of the United States of America.